Epcoritamab added to treatment for high-risk chronic lymphocytic leukemia
Tests epcoritamab in adults with chronic lymphocytic leukemia already taking a BTK inhibitor.
Plain-language title generated from the registry record
Registry title: Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
Key facts
- Where
- Orange, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Irvine
- Trial code
- NCT07819214
- Record updated
- 9 November 2026
- Original description
This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).Read full original descriptionShow less
Epcoritamab as Consolidation Therapy for High-risk Patients With Chronic Lymphocytic Leukemia on Bruton Tyrosine Kinase Inhibitor
This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).
Inclusion: Patients with CLL and at least 1 of the following risk factors:; ≥1 prior line of therapy before BTKi; 17p deletion and/or TP53 mutation; Complex karyotype (≥3 chromosomal abnormalities); Treated with a BTKi for ≥ 6 months; Receiving or able to obtain a commercial supply of BTKi; Measurable residual disease defined as the presence of CLL cells by conventional flow cytometry; ALC ≤10 K/mcL; Lymph nodes ≤5 cm in the longest diameter; Normal organ function and hematologic parameters; ECOG performance status of 0-1.
Exclusion: Current or prior Richter's transformation; Second active malignancy requiring treatment (excluding non-melanamatous skin cancers and cancers requiring hormonal therapies alone such as breast/prostate cancer); Active CNS involvement; Active immune-mediated cytopenias; Pregnant or breastfeeding.